Group 1 - Crescent Biopharma, Inc. is focused on developing CR-001, a tetravalent VEGF1 x PD-1 bispecific antibody aimed at treating solid tumors [1] - The company will present at the Jefferies London Healthcare Conference on November 19, 2024 [1][2] - Crescent has entered into an acquisition agreement with GlycoMimetics, Inc., and the combined entity will continue under the name Crescent [2] Group 2 - Crescent Biopharma's pipeline includes three programs that leverage validated biology to expedite the development of potentially best-in-class therapeutics for solid tumors [3]

Core Viewpoint - Monteverde & Associates PC is investigating GlycoMimetics, Inc. regarding a proposed merger with First Crescent Biopharma, Inc., which will significantly dilute GlycoMimetics shareholders' ownership in the combined company [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1][2]. - The firm is headquartered in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Merger Details - Under the proposed merger agreement, pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company, while pre-acquisition Crescent stockholders will own approximately 96.9% [1].

Group 1 - Monteverde & Associates PC is investigating GlycoMimetics, Inc. regarding a proposed merger with First Crescent Biopharma, Inc. [1] - Under the merger agreement, pre-acquisition GlycoMimetics stockholders are expected to own approximately 3.1% of the combined company, while pre-acquisition Crescent stockholders are expected to own approximately 96.9% [1] Group 2 - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report and has a successful track record in recovering money for shareholders [1][2] - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2]

Drug Development and Clinical Trials - The lead glycomimetic drug candidate, uproleselan, showed a median overall survival of 13.0 months in the treatment arm compared to 12.3 months in the placebo arm, but the difference was not statistically significant [64]. - In the subgroup of primary refractory patients, the median overall survival for those treated with uproleselan was 31.2 months compared to 10.1 months for the placebo group, indicating a significant benefit [66]. - A Cooperative Research and Development Agreement with the National Cancer Institute is ongoing for a Phase 2/3 trial of uproleselan, with enrollment of 267 patients completed in December 2021 [67]. - GMI-1687, an innovative antagonist of E-selectin, is being developed for vaso-occlusive events in sickle cell disease, with a Phase 1a trial completed in December 2023 [68]. - The Phase 3 trial of uproleselan did not achieve a statistically significant improvement in overall survival in the intent to treat population [64]. - The Phase 3 bridging study for uproleselan completed enrollment with 140 adult patients across 20 sites in Greater China, focusing on overall survival as the primary endpoint [73]. - The company has suspended a project agreement for the manufacture and supply of injectable uproleselan and has no binding obligation to acquire the product [94]. - The company has initiated the closure of all clinical sites and will incur close-out costs [94]. Financial Performance and Expenses - The company reported an accumulated deficit of $478.3 million as of June 30, 2024, and continues to incur operating losses [69]. - The company reported a net loss of $10.1 million for the three months ended June 30, 2024, compared to a net loss of $8.3 million in the same period in 2023, representing an increase of $1.8 million (22%) [85]. - Total costs and expenses for the three months ended June 30, 2024, were $10.4 million, an increase of $1.4 million (16%) from $8.9 million in the same period in 2023 [85]. - Research and development expenses for the three months ended June 30, 2024, increased by $2.2 million (54%) to $6.3 million compared to $4.1 million in the same period in 2023 [85]. - For the six months ended June 30, 2024, research and development expenses rose by $2.8 million (30%) to $12.3 million from $9.5 million in the same period in 2023 [86]. - General and administrative expenses decreased by $0.8 million (16%) for the three months ended June 30, 2024, and by $1.2 million (12%) for the six months ended June 30, 2024, compared to the same periods in 2023 [88]. - Interest income for the three months ended June 30, 2024, decreased by $409,000 (61%) to $262,000 compared to $671,000 in the same period in 2023 [85]. - Interest income decreased by $0.4 million (for three months) and $0.6 million (for six months) due to lower invested cash and cash equivalent balances compared to the same periods in 2023 [89]. - The company incurred a net loss of $36.9 million during 2023 [99]. Strategic Initiatives and Future Outlook - Following the Phase 3 trial results, the company initiated a strategic review process, which may include a merger, sale, or other strategic transactions [70]. - A workforce reduction plan was implemented, reducing the workforce by approximately 80% to maximize capital preservation [70]. - The company expects its current cash and cash equivalents to fund operations into the second quarter of 2025, but may need to raise additional capital or further reduce expenses [71]. - The company has no committed source of additional funding from debt or equity financings as of June 30, 2024 [99]. - The company sold 9,822,930 shares of common stock under the 2022 Sales Agreement in 2023, generating net proceeds of $28.7 million [91]. - Net cash used in operating activities for the six months ended June 30, 2024, was $19.4 million, compared to $18.6 million for the same period in 2023 [100]. - Net cash provided by financing activities during the six months ended June 30, 2024, consisted of proceeds from stock option exercises, while in 2023, it was primarily from sales of common stock [103]. Collaboration and Revenue - The company has entered into a collaboration with Apollomics for the development of uproleselan and GMI-1687 in Greater China [72]. - The company recognized $1.1 million in revenue from clinical supplies sold to Apollomics during the year ended December 31, 2021, but reported no sales during the six months ended June 30, 2024, or 2023 [74]. - The company has not generated any revenue from drug sales to date and does not expect to do so in the near future, relying primarily on upfront and milestone payments from collaboration agreements [77]. - The company received an upfront cash payment of $9.0 million and a $1.0 million milestone payment in September 2020, with potential further milestone payments totaling approximately $179.0 million and tiered royalties ranging from high single digits to 15% of net sales [73].

Financial Performance - The company reported an accumulated deficit of $467.2 million as of March 31, 2024, and expects to continue incurring operating losses over the next several years [96]. - The company has no revenue from drug sales and does not expect to generate revenue in the near future, relying on milestone payments from collaboration agreements [105]. - Net loss for Q1 2024 was $10,737,000, a decrease of $378,000 (4%) compared to a net loss of $10,359,000 in Q1 2023 [114]. - Interest income decreased by $204,000 (35%) to $378,000 in Q1 2024 due to lower cash and cash equivalent balances [118]. - As of March 31, 2024, the company had $31.3 million in cash and cash equivalents, with no committed source of additional funding [130]. - The company expects existing cash and cash equivalents to fund operating expenses through Q4 2024, but plans to reduce expenses to preserve capital [131]. - Net cash used in operating activities for Q1 2024 was $10,509,000, an improvement from $11,607,000 in Q1 2023 [132]. - The company sold 9,822,930 shares under the 2022 Sales Agreement in 2023, raising $28.7 million in net proceeds [120]. Drug Development - The lead drug candidate, uproleselan, showed a median overall survival of 13 months in patients treated with it, compared to 12.3 months in the placebo group during a Phase 3 trial [87]. - The company completed enrollment of 388 patients in a Phase 3 pivotal clinical trial for uproleselan in 2021, based on FDA guidance [86]. - A Cooperative Research and Development Agreement with the National Cancer Institute is in place for a Phase 2/3 trial testing uproleselan with standard chemotherapy, with 267 patients enrolled in the Phase 2 portion [88]. - The Phase 3 bridging study for uproleselan in Greater China has enrolled 140 patients, with overall survival as the primary endpoint [101]. - GMI-1687, an innovative E-selectin antagonist, completed enrollment of 40 subjects in a Phase 1a trial in December 2023 [92]. - The company is uncertain about the timing and costs associated with the development of its drug candidates, including uproleselan [125]. Capital Management - The company has raised capital primarily through private placements and collaboration agreements, with no approved drugs currently available for sale [95]. - The company plans to reduce operating expenses in the upcoming months to preserve capital, although this may not significantly extend the cash runway [97]. - A purchase commitment of $3,768,000 was entered into for raw materials to support the next commercial manufacturing campaign [123]. - The company received an upfront cash payment of $9.0 million from Apollomics for the development and commercialization of uproleselan and GMI-1687 in Greater China [100]. Expenses - Research and development expenses for Q1 2024 increased by $606,000 (11%) to $6,025,000 compared to Q1 2023 [114]. - General and administrative expenses decreased by $432,000 (8%) to $5,090,000 in Q1 2024, primarily due to lower personnel-related expenses [117].

Exhibit 99.2 Forward-Looking Statements GlycoMimetics GlycoMimetics Transforming Lives Glycobiology-based Therapeutics May 2024 | NASDAQ: GLYC To the extent that statements contained in this presentation are not descriptions of historical facts, thr statements reflecting the current beliefs and expectations of the management of GlycoMimetics, Inc. | "us," or "our"). Forward-looking statements contained in this presentation may include, but are not lin or projected timing of events, data readout and data ana ...

EXHIBIT 99.1 GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023 ROCKVILLE, Md.--(BUSINESS WIRE) – March 27, 2024-- GlycoMimetics, Inc. (Nasdaq: GLYC), a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2023. Cash and cash equivalents as of December 31, 2023, were $41.8 million. "With t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Commission file number 001-36177 GlycoMimetics, Inc. (Exact name of Registrant as specified in its charter) Delaware 06-1686563 (State or other jurisdiction of incorporation or organization) 9708 Medical Center Drive Rockville, Maryland 20850 (Address of principal executive offices) ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Exact name of registrant as specified in its charter) Delaware 06-1686563 (Stat ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR (I.R.S. Employer Identification No.) (240) 243-1201 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36177 GlycoMimetics, Inc. (Registrant's telephone number, i ...